Recent Quotes (30 days)

You have no recent quotes
chg | %

Concordia International Corp  

(Public, TSE:CXR)   Watch this stock  
Find more results for CXR
1.73
0.00 (0.00%)
Delayed:   11:31AM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.70 - 1.77
52 week 1.41 - 28.35
Open 1.73
Vol / Avg. 39,098.00/262,388.00
Mkt cap 89.29M
P/E     -
Div/yield     -
EPS -36.01
Shares 51.11M
Beta -2.43
Inst. own     -
Jun 9, 2017
Concordia International Corp Extraordinary Shareholders Meeting
May 12, 2017
Q1 2017 Concordia International Corp Earnings Release (Estimated)
May 10, 2017
Q1 2017 Concordia International Corp Earnings Call - Webcast
May 1, 2017
Concordia International Corp at Bloom Burton & Co. Healthcare Investor Conference
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -49.09% -161.01%
Operating margin 11.44% -115.46%
EBITD margin - 50.97%
Return on average assets -8.60% -29.16%
Return on average equity - -337.54%
Employees 516 -
CDP Score - -

Address

277 Lakeshore Rd E Suite 302
OAKVILLE, ON L6J 1H9
Canada
+1-905-8425150 (Phone)
+1-905-8425154 (Fax)

Website links

Description

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Officers and directors

Jordan M. Kupinsky J.D. Chairman of the Board
Age: 43
Wayne Kreppner President, Chief Operating Officer
Age: 41
Allan Oberman Chief Executive Officer, Director
Age: 58
David J. Price Chief Financial Officer
Graeme Duncan President - Company's International Segment
Arijit Mookerjee Managing Director, Chief Financial Officer - Operations
Adeel Ahmad Chief Financial Officer of AMCo
Francesco Tallarico Chief Legal Officer and Secretary
Patrick Vink M.D. Director
Age: 52
Douglas N. Deeth Independent Director
Age: 68